DE602006000080D1 - Kristallform von Asenapinmaleat - Google Patents

Kristallform von Asenapinmaleat

Info

Publication number
DE602006000080D1
DE602006000080D1 DE602006000080T DE602006000080T DE602006000080D1 DE 602006000080 D1 DE602006000080 D1 DE 602006000080D1 DE 602006000080 T DE602006000080 T DE 602006000080T DE 602006000080 T DE602006000080 T DE 602006000080T DE 602006000080 D1 DE602006000080 D1 DE 602006000080D1
Authority
DE
Germany
Prior art keywords
crystal form
asenapine maleate
asenapine
maleate
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006000080T
Other languages
English (en)
Other versions
DE602006000080T2 (de
Inventor
Gerhardus Johannes Heeres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006000080(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon NV filed Critical Organon NV
Publication of DE602006000080D1 publication Critical patent/DE602006000080D1/de
Application granted granted Critical
Publication of DE602006000080T2 publication Critical patent/DE602006000080T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
DE602006000080T 2005-04-07 2006-04-06 Kristallform von Asenapinmaleat Active DE602006000080T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102742 2005-04-07
EP05102969 2005-04-14
EP05102969 2005-04-14

Publications (2)

Publication Number Publication Date
DE602006000080D1 true DE602006000080D1 (de) 2007-10-04
DE602006000080T2 DE602006000080T2 (de) 2008-05-15

Family

ID=36617328

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006000080T Active DE602006000080T2 (de) 2005-04-07 2006-04-06 Kristallform von Asenapinmaleat
DE602006004463T Active DE602006004463D1 (de) 2005-04-07 2006-04-06 Kristallform von asenapinmaleat

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602006004463T Active DE602006004463D1 (de) 2005-04-07 2006-04-06 Kristallform von asenapinmaleat

Country Status (31)

Country Link
EP (2) EP1710245B1 (de)
JP (1) JP5058151B2 (de)
KR (1) KR101422843B1 (de)
AR (1) AR056306A1 (de)
AT (2) ATE418556T1 (de)
AU (1) AU2006231617B2 (de)
BR (1) BRPI0609741A8 (de)
CA (1) CA2603509C (de)
CY (2) CY1106902T1 (de)
DE (2) DE602006000080T2 (de)
DK (2) DK1710245T3 (de)
DO (1) DOP2006000082A (de)
ES (2) ES2318742T3 (de)
GT (1) GT200600135A (de)
HN (1) HN2006014095A (de)
HR (1) HRP20070429T3 (de)
IL (1) IL186355A (de)
MX (1) MX2007012445A (de)
MY (1) MY137969A (de)
NO (1) NO340520B1 (de)
NZ (1) NZ562124A (de)
PE (1) PE20061311A1 (de)
PL (2) PL1917267T3 (de)
PT (2) PT1917267E (de)
RS (1) RS50532B (de)
RU (1) RU2405786C2 (de)
SI (2) SI1710245T1 (de)
SV (1) SV2006002473A (de)
TW (1) TWI364423B (de)
UY (1) UY29459A1 (de)
WO (1) WO2006106135A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831514A (en) * 2006-10-06 2008-08-01 Organon Nv Amorphous asenapine and processes for preparing same
US8658687B2 (en) * 2009-06-24 2014-02-25 Merck Sharp & Dohme Corp. Injectable formulations containing asenapine and method of treatment using same
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (de) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphe Formen von Asenapinmaleat und Verfahren zur ihrer Herstellung
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524920A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Formen von Asenapin-Hydrochloridsalz
EP2524919A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Salze von Asenapin mit organischen Di-Säuren und Tri-Säuren
EP2524921A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Salze von Asenapin
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (de) 2011-09-21 2013-03-27 Hexal AG Komprimierte orale Dosierform für Asenapinmaleat
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
TWI603748B (zh) * 2012-07-26 2017-11-01 久光製藥股份有限公司 Adhesive
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
US9597291B2 (en) 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3558276A1 (de) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit asenapin und polysiloxan oder polyisobutylen
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
RU2139051C1 (ru) * 1994-03-02 1999-10-10 Акцо Нобель Н.В. Сублингвальная или трансбуккальная фармацевтическая композиция
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
JP5058151B2 (ja) 2012-10-24
EP1917267B1 (de) 2008-12-24
SI1710245T1 (sl) 2007-12-31
ATE418556T1 (de) 2009-01-15
ATE370954T1 (de) 2007-09-15
PT1710245E (pt) 2007-10-03
EP1710245A1 (de) 2006-10-11
MX2007012445A (es) 2007-11-07
BRPI0609741A8 (pt) 2018-03-13
EP1917267A1 (de) 2008-05-07
CY1106902T1 (el) 2012-09-26
DOP2006000082A (es) 2006-11-30
PE20061311A1 (es) 2007-02-09
JP2008534656A (ja) 2008-08-28
PT1917267E (pt) 2009-02-04
TWI364423B (en) 2012-05-21
TW200722428A (en) 2007-06-16
NO20075142L (no) 2007-11-05
AU2006231617B2 (en) 2010-06-03
CA2603509C (en) 2013-12-03
CA2603509A1 (en) 2006-10-12
KR20080005253A (ko) 2008-01-10
AU2006231617A1 (en) 2006-10-12
NZ562124A (en) 2010-07-30
AR056306A1 (es) 2007-10-03
HN2006014095A (es) 2010-08-19
WO2006106135A1 (en) 2006-10-12
IL186355A0 (en) 2008-01-20
UY29459A1 (es) 2006-11-30
SI1917267T1 (sl) 2009-04-30
RU2007141198A (ru) 2009-05-20
BRPI0609741A2 (pt) 2010-04-27
ES2318742T3 (es) 2009-05-01
RS50532B (sr) 2010-05-07
PL1917267T3 (pl) 2009-06-30
RU2405786C2 (ru) 2010-12-10
DE602006000080T2 (de) 2008-05-15
HRP20070429T3 (en) 2007-11-30
DK1917267T3 (da) 2009-04-14
DK1710245T3 (da) 2007-12-03
GT200600135A (es) 2006-11-07
SV2006002473A (es) 2009-11-24
EP1710245B1 (de) 2007-08-22
DE602006004463D1 (de) 2009-02-05
NO340520B1 (no) 2017-05-02
ES2293626T3 (es) 2008-03-16
MY137969A (en) 2009-04-30
CY1108742T1 (el) 2014-04-09
IL186355A (en) 2016-05-31
KR101422843B1 (ko) 2014-07-24
PL1710245T3 (pl) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE418556T1 (de) Kristallform von asenapinmaleat
ZA200708493B (en) Crystal form of asenapine maleate
DE602005012267D1 (de) N von geräten
DE602005011285D1 (de) Formmasse von polymer
DK1720866T3 (da) Fremgangsmåde
DK1737304T3 (da) Flydende koncentreret formel
FR2872069B1 (fr) Vibrateur vertical
ATE414693T1 (de) Neuartige cis-imidazoline
DK1702543T3 (da) Kapsel med forseglingsmidler
DE602005024107D1 (de) Flüssigkristall wiedergabeanordnung
NO20042425L (no) Anordning for algeproduksjon
ATE460162T1 (de) Neue kristallformen von irinotecan-hydrochlorid
MA28698B1 (fr) Dicetopiperazines substituees utilisees comme antagonistes des oxytocines
AT500499A3 (de) Mittelpunktbestimmung von justiermarken
NO20043305D0 (no) Preparation of lodixanol
NO20070299L (no) Novel heterocyclic compounds
DE602005012754D1 (de) Kristalloszillator
DE602004021510D1 (de) Gangslichts polarisationserhaltender wellenleiterbauelemente
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
SE0402103D0 (sv) Novel compounds
FI20041228A0 (fi) Hiomakiven kunto
ATA7132004A (de) Formstein
UA11802S (uk) Черепиця фронтонна
UA11801S (uk) Черепиця фронтонна
SE0400661D0 (sv) Husgrund

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1710245

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE